扶正抗癌方干预的晚期非小细胞肺癌长期生存预后分析

发布时间：2018-10-08 16:20

【摘要】：目的：探讨分析扶正抗癌方干预的晚期非小细胞肺癌长期生存患者(生存期2年)的预后相关因子,为优化提高晚期非小细胞肺癌中西医结合治疗方案提供临床参考依据。方法：本研究采用回顾性研究方法,收集广东省中医院肿瘤科2006年1月至2015年12月于吴万垠教授门诊以及病房接受扶正抗癌方治疗的晚期非小细胞肺癌、获得长期生存病例(生存期2年),将符合纳入标准的113例患者,通过对生存时间可能产生影响的个人临床特征、肿瘤及治疗相关因子共39项进行分析。并建立数据库,运用Kaplan-Meier法联合Log-Rank检验进行单因素分析；运用Cox比例风险回归模型进行多因素分析(检验水平α=0.05),筛选危险因子和保护因子。结果：截至2016年3月1日,共纳入113例患者,其中56例死亡,其余57例为截尾数据。所有患者3、4、5年生存率分别为51.3%、26.5%、12.4%,其中位生存时间为36.4月(95% CI：32.0-40.8月)。单因素分析显示性别、吸烟史、PS评分、体重减轻、原发肿瘤大小、合并胸水、病理类型、淋巴结分期、中医证型、扶正抗癌方干预时间与晚期非小细胞肺癌长期生存相关(PO.05)。多因素分析显示PS评分、原发肿瘤大小、淋巴结分期、中医证型、扶正抗癌方干预时间为晚期非小细胞肺癌长期生存的独立预后因素。其中,PS≥12分、原发肿瘤7cm、 N3、气阴两虚型、热毒炽盛型、扶正抗癌方干预时间≤24个月,为晚期非小细胞肺癌长期生存的预后危险因子。结论：1.PS评分、原发肿瘤大小、淋巴结分期、中医证型、扶正抗癌方干预时间能影响晚期非小细胞肺癌长期生存。2.中药扶正抗癌方在延长晚期非小细胞肺癌生存时间方面有一定的治疗作用,值得进一步研究。
[Abstract]:Objective: to investigate the prognostic factors of patients with advanced non-small cell lung cancer (NSCLC) treated with Fuzheng Fang (Fuzheng Fang), and to provide a clinical reference for optimizing and improving the treatment of advanced non-small cell lung cancer (NSCLC) with combination of traditional Chinese and western medicine. Methods: a retrospective study was conducted to collect advanced non-small cell lung cancer (NSCLC) from January 2006 to December 2015 in Professor Wu Wanyin's outpatient clinic and ward treated with Fuzheng Fang. The long-term survival cases (survival time 2 years) were obtained. 113 patients who met the inclusion criteria were analyzed through 39 items of individual clinical characteristics, tumor and treatment-related factors that might have an impact on survival time. The database was established, and the single factor analysis was carried out by Kaplan-Meier method combined with Log-Rank test, and the multivariate analysis was carried out by using the Cox proportional risk regression model (test level 伪 0. 05), and the risk factors and protection factors were screened. Results: as of March 1, 2016, 113 patients were included, 56 of whom died and the remaining 57 were amputations. The 5-year survival rates of all patients were 51.3% and 26.5%, respectively, and the survival time was 36.4 months (95% CI:32.0-40.8 / month). Univariate analysis showed that sex, smoking history and PS score, weight loss, primary tumor size, combined pleural effusion, pathological type, lymph node staging, TCM syndrome type and intervention time of Fuzheng Fang were associated with long-term survival of advanced non-small cell lung cancer (PO.05). Multivariate analysis showed that PS score, primary tumor size, lymph node staging, TCM syndrome type and intervention time of Fuzheng Fang were independent prognostic factors for long-term survival of advanced non-small cell lung cancer. Among them, PS 鈮，

本文编号：2257433